Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: A computational analysis

Journal of Applied Physiology

Volumn 112, Issue 8, 2012, Pages 1383-1392

  Deonikar, Prabhakar ^a   Kavdia, Mahendra ^a  

^a Wayne State University   (United States)

Author keywords

Mathematical model; Microcirculation; Nitric oxide; Red blood cells

Indexed keywords

HEMOGLOBIN; NITRIC OXIDE;

ARTERIOLE; ARTICLE; BIOAVAILABILITY; ERYTHROCYTE; HEMOLYSIS; HUMAN; METABOLISM; MICROCIRCULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; THEORETICAL MODEL; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR RESISTANCE;

ANEMIA, SICKLE CELL; ARTERIOLES; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; ERYTHROCYTES; HEMOGLOBINS; HEMOLYSIS; HUMANS; HYPERTENSION, PULMONARY; MICROCIRCULATION; MODELS, THEORETICAL; NITRIC OXIDE; VASCULAR RESISTANCE;

EID: 84860317131     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01173.2011     Document Type: Article

References (77)

1. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74: 3203-3207, 1977.
2. Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, Orringer EP. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 134: 109-115, 2006.
3. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion 46: 105-110, 2006.
4. Buerk DG, Ances BM, Greenberg JH, Detre JA. Temporal dynamics of brain tissue nitric oxide during functional forepaw stimulation in rats. Neuroimage 18: 1-9, 2003.
5. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 116: 687-692, 2010.
6. Butler AR, Megson IL, Wright PG. Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim Biophys Acta 1425: 168-176, 1998.
7. Carlsen E, Comroe JH Jr. The rate of uptake of carbon monoxide and of nitric oxide by normal human erythrocytes and experimentally produced spherocytes. J Gen Physiol 42: 83-107, 1958.
8. Cassoly R, Gibson Q. Conformation, co-operativity and ligand binding in human hemoglobin. J Mol Biol 91: 301-313, 1975.
9. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 84: 643-649, 1994.
10. Chen K, Pittman RN, Popel AS. Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. Antioxid Redox Signal 10: 1185-1198, 2008.
11. Chen K, Pittman RN, Popel AS. Vascular smooth muscle NO exposure from intraerythrocytic SNOHb: a mathematical model. Antioxid Redox Signal 9: 1097-1110, 2007.
12. Cheung AT, Chen PC, Larkin EC, Duong PL, Ramanujam S, Tablin F, Wun T. Microvascular abnormalities in sickle cell disease: a computerassisted intravital microscopy study. Blood 99: 3999-4005, 2002.
13. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 83: 19-25, 2008.
14. Deonikar P, Kavdia M. A computational model for nitric oxide, nitrite and nitrate biotransport in the microcirculation: effect of reduced nitric oxide consumption by red blood cells and blood velocity. Microvasc Res 80: 464-476, 2010.
15. Deonikar P, Kavdia M. Extracellular diffusion and permeability effects on NO-RBCs interactions using an experimental and theoretical model. Microvasc Res 79: 47-55, 2009.
16. Deonikar P, Kavdia M. An integrated computational and experimental model of nitric oxide-red blood cell interactions. Ann Biomed Eng 38: 357-370, 2010.
17. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, Lemon DD. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 16: 672-676, 1998.
18. Doyle MP, Hoekstra JW. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem 14: 351-358, 1981.
19. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem 40: 63-279, 1990.
20. Eich RF, Li T, Lemon DD, Doherty DH, Curry SR, Aitken JF, Mathews AJ, Johnson KA, Smith RD, Phillips GN Jr, Olson JS. Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry 35: 6976-6983, 1996.
21. Embury SH, Mohandas N, Paszty C, Cooper P, Cheung AT. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J Clin Invest 103: 915-920, 1999.
22. French JA, 2nd Kenny D, Scott JP, Hoffmann RG, Wood JD, Hudetz AG, Hillery CA. Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood 89: 4591-4599, 1997.
23. Fung YC. Biomechanics: Circulation. New York: Springer-Verlag, 1997, p. 571.
24. Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, Kim-Shapiro DB, Machado R, Morris CR, Steinberg MH, Vichinsky EP. Pulmonary hypertension and NO in sickle cell. Blood 116: 852-854, 2010.
25. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350: 886-895, 2004.
26. Haas TL, Duling BR. Morphology favors an endothelial cell pathway for longitudinal conduction within arterioles. Microvasc Res 53: 113-120, 1997.
27. Han TH, Liao JC. Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier. Biochim Biophys Acta 1723: 135-142, 2005.
28. Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 33: 1037-1043, 2002.
29. Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, Richards SJ, Bessler M, Bell L, Hillmen P, Gladwin MT. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 149: 414-425, 2010.
30. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109: 3088-3098, 2007.
31. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium- derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84: 9265-9269, 1987.
32. Jeffers A, Gladwin MT, Kim-Shapiro DB. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic Biol Med 41: 1557-1565, 2006.
33. Kato GJ, McGowan V, Machado RF, Little JA, Taylor Jt Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107: 2279-2285, 2006.
34. Kato GJ, Wang Z, Machado RF, Blackwelder WC, Taylor JG VI, Hazen SL. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 145: 506-513, 2009.
35. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest 114: 1136-1145, 2004.
36. Kavdia M. A computational model for free radicals transport in the microcirculation. Antioxid Redox Signal 8: 1103-1111, 2006.
37. Kavdia M, Lewis RS. Free radical profiles in an encapsulated pancreatic cell matrix model. Ann Biomed Eng 30: 721-730, 2002.
38. Kavdia M, Popel AS. Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure. J Appl Physiol 97: 293-301, 2004.
39. 2 carriers. Microvasc Res 66: 49-58, 2003.
40. Kavdia M, Tsoukias NM, Popel AS. Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. Am J Physiol Heart Circ Physiol 282: H2245-H2253, 2002.
41. Kim S, Kong RL, Popel AS, Intaglietta M, Johnson PC. Temporal and spatial variations of cell-free layer width in arterioles. Am J Physiol Heart Circ Physiol 293: H1526-H1535, 2007.
42. Lamkin-Kennard K, Jaron D, Buerk DG. Modeling the regulation of oxygen consumption by nitric oxide. Adv Exp Med Biol 510: 145-149, 2003.
43. Lancaster JR Jr. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 91: 8137-8141, 1994.
44. Landburg PP, Teerlink T, van Beers EJ, Muskiet FA, Kappers- Klunne MC, van Esser JW, Mac Gillavry MR, Biemond BJ, Brandjes DP, Duits AJ, Schnog JJ. Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension. Haematologica 93: 1410-1412, 2008.
45. Lewis RS, Deen WM. Kinetics of the reaction of nitric oxide with oxygen in aqueous solutions. Chem Res Toxicol 7: 568-574, 1994.
46. Liao JC, Hein TW, Vaughn MW, Huang KT, Kuo L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci USA 96: 8757-8761, 1999.
47. Lipowsky HH, Usami S, Chien S. Human SS red cell rheological behavior in the microcirculation of cremaster muscle. Blood Cells 8: 113-126, 1982.
48. Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR Jr. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 273: 18709-18713, 1998.
49. Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, Taveira-DaSilva AM, Ballas SK, Blackwelder W, Xu X, Hunter L, Barton B, Waclawiw M, Castro O, Gladwin MT. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 296: 310-318, 2006.
50. Malinski T, Radomski MW, Taha Z, Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun 194: 960-965, 1993.
51. Minneci PC, Deans KJ, Zhi H, Yuen PS, Star RA, Banks SM, Schechter AN, Natanson C, Gladwin MT, Solomon SB. Hemolysisassociated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest 115: 3409-3417, 2005.
52. Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, Onyekwere O, Nouraie M, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica 94: 340-347, 2009.
53. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, pharmacology. Pharmacol Rev 43: 109-142, 1991.
54. Morris CR, Kuypers FA, Kato GJ, Lavrisha L, Larkin S, Singer T, Vichinsky EP. Hemolysis-associated pulmonary hypertension in thalassemia. Ann NY Acad Sci 1054: 481-485, 2005.
55. Munn LL, Dupin MM. Blood cell interactions and segregation in flow. Ann Biomed Eng 36: 534-544, 2008.
56. Pawlak MA, Krejza J, Rudzinski W, Kwiatkowski JL, Ichord R, Jawad AF, Tomaszewski M, Melhem ER. Sickle cell disease: ratio of blood flow velocity of intracranial to extracranial cerebral arteries-initial experience. Radiology 251: 525-534, 2009.
57. Pittman RN, Duling BR. Effects of altered carbon dioxide tension on hemoglobin oxygenation in hamster cheek pouch microvessels. Microvasc Res 13: 211-224, 1977.
58. Pohl U, Lamontagne D. Impaired tissue perfusion after inhibition of endothelium-derived nitric oxide. Basic Res Cardiol 86, Suppl 2: 97-105, 1991.
59. Popel AS, Gross JF. Analysis of oxygen diffusion from arteriolar networks. Am J Physiol Heart Circ Physiol 237: H681-H689, 1979.
60. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO III, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8: 1383-1389, 2002.
61. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Nienhuis AW, Bonner RF. Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med 311: 1534-1538, 1984.
62. Rohlfs RJ, Bruner E, Chiu A, Gonzales A, Gonzales ML, Magde D, Magde MD Jr, Vandegriff KD, Winslow RM. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J Biol Chem 273: 12128-12134, 1998.
63. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293: 1653-1662, 2005.
64. Schnog JB, Teerlink T, van der Dijs FP, Duits AJ, Muskiet FA. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol 84: 282-286, 2005.
65. Sebastiani P, Nolan VG, Baldwin CT, Abad-Grau MM, Wang L, Adewoye AH, McMahon LC, Farrer LA, Taylor JGt Kato GJ, Gladwin MT, Steinberg MH. A network model to predict the risk of death in sickle cell disease. Blood 110: 2727-2735, 2007.
66. Secomb TW, Hsu R, Pries AR. A model for red blood cell motion in glycocalyx-lined capillaries. Am J Physiol Heart Circ Physiol 274: H1016-H1022, 1998.
67. Sharan M, Popel AS. A two-phase model for flow of blood in narrow tubes with increased effective viscosity near the wall. Biorheology 38: 415-428, 2001.
68. Steinberg MH. Management of sickle cell disease. N Engl J Med 340: 1021-1030, 1999.
69. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 364: 1343-1360, 2004.
70. Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol 74: 626-628, 1994.
71. Tsoukias NM, Popel AS. Erythrocyte consumption of nitric oxide in presence and absence of plasma-based hemoglobin. Am J Physiol Heart Circ Physiol 282: H2265-H2277, 2002.
72. Urbaitis BK, Razynska A, Corteza Q, Fronticelli C, Bucci E. Intravascular retention and renal handling of purified natural and intramolecularly cross-linked hemoglobins. J Lab Clin Med 117: 115-121, 1991.
73. Vaughn MW, Kuo L, Liao JC. Estimation of nitric oxide production and reaction rates in tissue by use of a mathematical model. Am J Physiol Heart Circ Physiol 274: H2163-H2176, 1998.
74. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115: 2354-2363, 2010.
75. Walmsley JG, Gore RW, Dacey RG Jr, Damon DN, Duling BR. Quantitative morphology of arterioles from the hamster cheek pouch related to mechanical analysis. Microvasc Res 24: 249-271, 1982.
76. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Kenangalem E, Piera K, Granger DL, Lopansri BK, Weinberg JB, Price RN, Duffull SB, Celermajer DS, Anstey NM. Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis 200: 1522-1529, 2009.
77. Zhang J, Johnson PC, Popel AS. Effects of erythrocyte deformability and aggregation on the cell-free layer and apparent viscosity of microscopic blood flows. Microvasc Res 77: 265-272, 2009.